192 related articles for article (PubMed ID: 36080182)
1. mTORC2 Is the Major Second Layer Kinase Negatively Regulating FOXO3 Activity.
Jimenez L; Amenabar C; Mayoral-Varo V; Mackenzie TA; Ramos MC; Silva A; Calissi G; Grenho I; Blanco-Aparicio C; Pastor J; Megías D; Ferreira BI; Link W
Molecules; 2022 Aug; 27(17):. PubMed ID: 36080182
[TBL] [Abstract][Full Text] [Related]
2. Evidence for AKT-independent regulation of FOXO1 and FOXO3 in haematopoietic stem and progenitor cells.
Liang R; Rimmelé P; Bigarella CL; Yalcin S; Ghaffari S
Cell Cycle; 2016; 15(6):861-7. PubMed ID: 26929388
[TBL] [Abstract][Full Text] [Related]
3. Screening Health-Promoting Compounds for Their Capacity to Induce the Activity of FOXO3.
Jimenez L; Silva A; Calissi G; Grenho I; Monteiro R; Mayoral-Varo V; Blanco-Aparicio C; Pastor J; Bustos V; Bracher F; Megías D; Ferreira BI; Link W
J Gerontol A Biol Sci Med Sci; 2022 Aug; 77(8):1485-1493. PubMed ID: 34508571
[TBL] [Abstract][Full Text] [Related]
4. Regulation of hepatic insulin-like growth factor-binding protein-1 gene expression by insulin: central role for mammalian target of rapamycin independent of forkhead box O proteins.
Mounier C; Dumas V; Posner BI
Endocrinology; 2006 May; 147(5):2383-91. PubMed ID: 16455781
[TBL] [Abstract][Full Text] [Related]
5. The tumour suppressor FOXO3 is a key regulator of mantle cell lymphoma proliferation and survival.
Obrador-Hevia A; Serra-Sitjar M; Rodríguez J; Villalonga P; Fernández de Mattos S
Br J Haematol; 2012 Feb; 156(3):334-45. PubMed ID: 22107151
[TBL] [Abstract][Full Text] [Related]
6. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc.
Masui K; Tanaka K; Akhavan D; Babic I; Gini B; Matsutani T; Iwanami A; Liu F; Villa GR; Gu Y; Campos C; Zhu S; Yang H; Yong WH; Cloughesy TF; Mellinghoff IK; Cavenee WK; Shaw RJ; Mischel PS
Cell Metab; 2013 Nov; 18(5):726-39. PubMed ID: 24140020
[TBL] [Abstract][Full Text] [Related]
7. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
[TBL] [Abstract][Full Text] [Related]
8. FOXO3 is inhibited by oncogenic PI3K/Akt signaling but can be reactivated by the NSAID sulindac sulfide.
Weidinger C; Krause K; Mueller K; Klagge A; Fuhrer D
J Clin Endocrinol Metab; 2011 Sep; 96(9):E1361-71. PubMed ID: 21752881
[TBL] [Abstract][Full Text] [Related]
9. Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors.
Lee D; Sykes SM; Kalaitzidis D; Lane AA; Kfoury Y; Raaijmakers MH; Wang YH; Armstrong SA; Scadden DT
Stem Cell Reports; 2014 Nov; 3(5):832-40. PubMed ID: 25418727
[TBL] [Abstract][Full Text] [Related]
10. FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor.
Chen CC; Jeon SM; Bhaskar PT; Nogueira V; Sundararajan D; Tonic I; Park Y; Hay N
Dev Cell; 2010 Apr; 18(4):592-604. PubMed ID: 20412774
[TBL] [Abstract][Full Text] [Related]
11. Testosterone regulation of Akt/mTORC1/FoxO3a signaling in skeletal muscle.
White JP; Gao S; Puppa MJ; Sato S; Welle SL; Carson JA
Mol Cell Endocrinol; 2013 Jan; 365(2):174-86. PubMed ID: 23116773
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway.
Boreddy SR; Pramanik KC; Srivastava SK
Clin Cancer Res; 2011 Apr; 17(7):1784-95. PubMed ID: 21350002
[TBL] [Abstract][Full Text] [Related]
13. Regulation of cardiomyocyte proliferation and myocardial growth during development by FOXO transcription factors.
Evans-Anderson HJ; Alfieri CM; Yutzey KE
Circ Res; 2008 Mar; 102(6):686-94. PubMed ID: 18218983
[TBL] [Abstract][Full Text] [Related]
14. FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function.
Shats I; Gatza ML; Liu B; Angus SP; You L; Nevins JR
Cancer Res; 2013 Oct; 73(19):6056-67. PubMed ID: 23966291
[TBL] [Abstract][Full Text] [Related]
15. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1.
Guertin DA; Stevens DM; Thoreen CC; Burds AA; Kalaany NY; Moffat J; Brown M; Fitzgerald KJ; Sabatini DM
Dev Cell; 2006 Dec; 11(6):859-71. PubMed ID: 17141160
[TBL] [Abstract][Full Text] [Related]
16. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA
Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
[TBL] [Abstract][Full Text] [Related]
17. TGF-β-induced phosphorylation of Akt and Foxo transcription factors negatively regulates induced regulatory T cell differentiation.
Kurebayashi Y; Baba Y; Minowa A; Nadya NA; Azuma M; Yoshimura A; Koyasu S; Nagai S
Biochem Biophys Res Commun; 2016 Nov; 480(1):114-119. PubMed ID: 27697523
[TBL] [Abstract][Full Text] [Related]
18. FoxO proteins' nuclear retention and BH3-only protein Bim induction evoke mitochondrial dysfunction-mediated apoptosis in berberine-treated HepG2 cells.
Shukla S; Rizvi F; Raisuddin S; Kakkar P
Free Radic Biol Med; 2014 Nov; 76():185-99. PubMed ID: 25128467
[TBL] [Abstract][Full Text] [Related]
19. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.
Jhanwar-Uniyal M; Dominguez JF; Mohan AL; Tobias ME; Gandhi CD
Adv Biol Regul; 2022 Jan; 83():100854. PubMed ID: 34996736
[TBL] [Abstract][Full Text] [Related]
20. FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway.
Lin A; Piao HL; Zhuang L; Sarbassov dos D; Ma L; Gan B
Cancer Res; 2014 Mar; 74(6):1682-93. PubMed ID: 24448243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
